Amarin Corp Plc (AMRN)

[ziploc_1]

Section 8 of the Hatch Waxman act has resulted in many infringements by generic cos. with consequent lawsuits

"Section viii of the Hatch-Waxman Act permits an Abbreviated New Drug Application (ANDA) applicant to obtain FDA approval to market a generic version of a drug for a non-patented use where the reference listed drug (RLD) has multiple indications, not all of which are covered by a method-of-use patent."

The obvious simple solution to this plethora of lawsuits is...for congress to amend the HW law so that...
medical insurance companies would be required to...
1.make lists of medicines with multiple indications in their formularies...declaring that they will provide coverage ONLY for the approved indications
2. require that prescriptions for medicines must always specify a particular indication in order to have insurance coverage for that patient prescription

Governments and medical insurance companies should approve of this amendment to HW...since it would reduce their costs while enabling patients to get the medicine they need for the correct indication.

As well as strengthening patent law..and reducing patent lawsuits